Navigation Links
AtheroNova Completes Successful Pre-IND Meeting with FDA on AHRO-001
Date:10/26/2011

IRVINE, Calif., Oct. 26, 2011 /PRNewswire/ -- AtheroNova Inc. (OTCBB: AHRO), a biotech company focused on the research and development of compounds to regress atherosclerotic plaque, today announced that it has completed its pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration (FDA). During the meeting, the FDA provided guidance on the development plan of AHRO-001, AtheroNova's lead patent-pending compound for the prevention and regression of atherosclerotic plaque. The goal of the pre-IND meeting was to obtain clarification on the nonclinical, clinical and chemical, manufacturing and control (CMC) requirements that need to be met in order to submit an acceptable IND.

"Our meeting with the FDA represents another important step in our clinical drug development plan. Our strategy to bring AHRO-001 into human clinical trials is now clear," said AtheroNova CEO Thomas Gardner. "Combined with our recent commitment from Maxwell Biotech Venture Fund to fund both Phase I and Phase II clinical trials and our licensing partnership with Maxwell Biotech Group, we are on track to commercialize novel therapies that can help millions of those suffering from cardiovascular disease."

About AHRO-001

AHRO-001 is AtheroNova's first novel application for the treatment and prevention of atherosclerosis. Atherosclerotic plaque is the primary, underlying cause of heart disease and stroke in industrialized countries. AHRO-001 uses certain natural compounds to regress atherosclerotic plaque deposits through a process known as delipidization. Delipidization dissolves plaques in artery walls, which are then removed by natural body processes. AtheroNova plans to develop multiple applications for its patents-pending compounds that can be used in pharmaceutical-grade products for the treatment of atherosclerosis. Atherosclerosis and related pharmaceutical costs run more than $41 billion annually in the United States alone.  Marke
'/>"/>

SOURCE AtheroNova Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
6. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
7. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
8. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
9. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
10. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
11. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... Minn. , Sept. 17, 2014  Rebiotix Inc. announced ... the company,s lead product candidate, RBX2660 (microbiota suspension) will be ... IDWeek 2014 conference in Philadelphia from ... be presented during the poster session on Thursday, October 9, ... C. difficile Infection: 60-Day Interim Analysis of the PUNCH-CD ...
(Date:9/17/2014)... , September 17, 2014 ... 17536, has shown positive data in a Phase 2a ... neuropathy , Glenmark Pharmaceuticals today ... Ankyrin 1 (TRPA1) antagonist, GRC 17536 has shown positive ... multi-centre, proof of concept study conducted on 138 patients ...
(Date:9/17/2014)... 2014  Members of the physician IT team ... announced today that the enterprise is working with ... sharing capabilities and provide immediate cluster fail over ... addition, the Dicom Systems enterprise imaging solutions will ... to more effectively deliver the right images to ...
Breaking Medicine Technology:PUNCH CD Study Drug Targeting Recurrent C. difficile Infection to be Presented at IDWeek 2014 2PUNCH CD Study Drug Targeting Recurrent C. difficile Infection to be Presented at IDWeek 2014 3PUNCH CD Study Drug Targeting Recurrent C. difficile Infection to be Presented at IDWeek 2014 4Glenmark's TRPA1 Antagonist 'GRC 17536' Shows Positive Data in a Proof of Concept Study 2Glenmark's TRPA1 Antagonist 'GRC 17536' Shows Positive Data in a Proof of Concept Study 3Dicom Systems' Innovative Software Provides Enhanced Imaging Sharing Capabilities, as Well as Connection Reliability in the Case of Network Failure 2Dicom Systems' Innovative Software Provides Enhanced Imaging Sharing Capabilities, as Well as Connection Reliability in the Case of Network Failure 3
... CARY, N.C., March 15, 2011 Saffron ... firm providing Natural Intelligence(1) solutions for business and ... leaders to its corporate Advisory Board . ... business-technology acumen, rich global business experience, and broad ...
... XTIO2 INC . (XTI) presented ... XTI ANTI-GERM / ANTI-VOC / ANTI-ALLERGY SYSTEM , consisting ...  Nano-Facemask . It is the world,s most effective preventive ... air and contact surfaces. The unique nanocoating protects people ...
Cached Medicine Technology:Saffron Technology Adds Seasoned Business Executives to Advisory Board 2Saffron Technology Adds Seasoned Business Executives to Advisory Board 3OSCAR® Nominees Receive (XTIO2 INC.) XTI 360™ Nano Coating Anti-Germ System 2OSCAR® Nominees Receive (XTIO2 INC.) XTI 360™ Nano Coating Anti-Germ System 3
(Date:9/17/2014)... September 17, 2014 Why are Asian Americans at ... Americans, and prone to develop the disease at lower ... in the transition from traditional high-fiber, low-fat Asian diets ... for those of Asian heritage, says George King, M.D., ... Diabetes Center and the senior author of the study. ...
(Date:9/17/2014)... GA (PRWEB) September 17, 2014 Leading ... to announce the launch of its new vegan and ... is extremely effective and provided the results skincare testers ... to create a gentle yet active mask that provided ... Lake Louise.” , This Sugar Cane Fruit Mask combines ...
(Date:9/17/2014)... The Delta Dental Community Care Foundation announced today ... Health Foundation: America’s ToothFairy (NCOHF) to support oral health ... Zone Program® in California. , The Orange County NCOHF ... local constituent groups and stakeholders in a comprehensive approach ... its devastating effects on local families. The support of ...
(Date:9/17/2014)... 17, 2014 (HealthDay News) -- Managing diabetes, quitting smoking, ... weight can reduce the risk for dementia -- even ... The World Alzheimer Report 2014, commissioned by Alzheimer,s Disease ... dementia by 50 percent. The study noted that obesity ... diabetes as well as high blood pressure. ...
(Date:9/17/2014)... WASHINGTON -- The U.S. health care system is not ... the end of life and those of their families, ... a new report from the Institute of Medicine. ... approach to end-of-life care that integrates traditional medical care ... sustainable. The committee called for more "advance care ...
Breaking Medicine News(10 mins):Health News:In Joslin trial, Asian Americans lower insulin resistance on traditional diet 2Health News:In Joslin trial, Asian Americans lower insulin resistance on traditional diet 3Health News:EcoBeauty Brand Lotus Moon Unveils New Gluten-Free Sugar Cane Fruit Mask 2Health News:Delta Dental Community Care Foundation Donation to America's ToothFairy Helps Deliver Critical Services 2Health News:Healthy Lifestyle Changes Linked to Reduced Risk for Dementia 2Health News:Healthy Lifestyle Changes Linked to Reduced Risk for Dementia 3Health News:US health system not properly designed to meet needs of patients nearing end of life, says IOM 2Health News:US health system not properly designed to meet needs of patients nearing end of life, says IOM 3Health News:US health system not properly designed to meet needs of patients nearing end of life, says IOM 4Health News:US health system not properly designed to meet needs of patients nearing end of life, says IOM 5
... in Complex Rehab IndustryWILKES-BARRE, Pa., March 11 James ... years of experience, has joined Alliance Seating & ... accredited complex rehab companies. Conwell is an Assistive ... Supplier (CRTS) in Wilkes-Barre, Pa., for ASM ( www.alliance-seating.com ...
... Prevention, Treatment and Care Services for People around ... March 11 Late yesterday the ... Omnibus Appropriations bill for fiscal year 2009. ... last week, contains an appropriation of $900 million ...
... The U.S. Agency for International Development (USAID) ... launched a new program to reduce HIV vulnerability of ... The three-year, $5.1 million project is funded by the ... administered by USAID . A recent release study ...
... of cancer cells and their frequent divisions have their ... cells. Their metabolism runs at full speed and requires ... of iron in the cell lead to the production ... these, the cell inactivates free iron by binding it ...
... Amex: FHC ) today announced that it will ... of the FC2 Female Condom(R) on Thursday, March ... Company announced its receipt of FDA approval for the ... Shareholders and other interested parties may participate in the conference ...
... ROSEMONT, Ill., March 11 /PRNewswire-USNewswire/ -- Orthopaedic surgeon ... of Councilors (BOC) of the American Academy of ... the Venetian Sands Expo Center in Las Vegas. He ... "As Secretary, I will be one of the voices for ...
Cached Medicine News:Health News:Veteran Rehab Specialist, James Conwell, Joins Fast-Growing Alliance Seating & Mobility in Pennsylvania 2Health News:Congress Approves FY2009 Omnibus Appropriations Bill with $900 Million for The Global Fund 2Health News:USAID and IOM Announce HIV Prevention and Care for Farm Workers 2Health News:The Female Health Company Schedules Conference Call to Discuss FDA Approval of FC2 Female Condom(R) for March 12, 2009 2Health News:The Female Health Company Schedules Conference Call to Discuss FDA Approval of FC2 Female Condom(R) for March 12, 2009 3Health News:David Teuscher, MD, Elected Secretary of Academy Board of Councilors 2
5.5 pointed curved blade. Octagonal handle....
2 mm wide curved tip. Round handle....
3 mm disposable Lance blade. Can fit in to the N0521 Storz handle....
Consist of 6 disposable bevel blades (N0522) and chuck handle (0521). Malleable shafts. Designated most popular model or size....
Medicine Products: